drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00641 | DB08873 | 467 | 74 | [
"DDInter1675",
"DDInter221"
] | Simvastatin | Boceprevir | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Major | 2 | [
[
[
467,
25,
74
]
],
[
[
467,
6,
4973
],
[
4973,
45,
74
]
],
[
[
467,
21,
28769
],
[
28769,
60,
74
]
],
[
[
467,
24,
72
],
[
72,
23,... | [
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Simvastatin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Bocepre... | Simvastatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Boceprevir (Compound)
Simvastatin (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Boceprevir (Compound)
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Eltr... |
DB01394 | DB11718 | 1,554 | 927 | [
"DDInter431",
"DDInter640"
] | Colchicine | Encorafenib | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1554,
24,
927
]
],
[
[
1554,
63,
112
],
[
112,
23,
927
]
],
[
[
1554,
25,
1491
],
[
1491,
24,
927
]
],
[
[
1554,
63,
770
],
[
770,
... | [
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Colchicine may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may... |
DB00427 | DB00906 | 1,233 | 1,567 | [
"DDInter1879",
"DDInter1801"
] | Triprolidine | Tiagabine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor. | Moderate | 1 | [
[
[
1233,
24,
1567
]
],
[
[
1233,
24,
530
],
[
530,
24,
1567
]
],
[
[
1233,
24,
537
],
[
537,
63,
1567
]
],
[
[
1233,
63,
1594
],
[
1594,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Tiagabine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cycl... |
DB00489 | DB01041 | 17 | 770 | [
"DDInter1704",
"DDInter1789"
] | Sotalol | Thalidomide | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
17,
24,
770
]
],
[
[
17,
21,
28789
],
[
28789,
60,
770
]
],
[
[
17,
25,
609
],
[
609,
63,
770
]
],
[
[
17,
25,
1557
],
[
1557,
2... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Sotalol",
"{u} (Compound) causes {v} (Side Effect)",
"Loss of consciousness"
],
[
"Loss of consciousness",
"{u} (S... | Sotalol (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Thalidomide (Compound)
Sotalol may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00736 | DB11703 | 660 | 405 | [
"DDInter676",
"DDInter9"
] | Esomeprazole | Acalabrutinib | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
660,
25,
405
]
],
[
[
660,
64,
1230
],
[
1230,
24,
405
]
],
[
[
660,
24,
1297
],
[
1297,
63,
405
]
],
[
[
660,
24,
478
],
[
478,
... | [
[
[
"Esomeprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Esomeprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Citalopram",
... | Esomeprazole may lead to a major life threatening interaction when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat... |
DB00782 | DB09128 | 1,123 | 1,241 | [
"DDInter1535",
"DDInter231"
] | Propantheline | Brexpiprazole | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
1123,
24,
1241
]
],
[
[
1123,
24,
407
],
[
407,
63,
1241
]
],
[
[
1123,
24,
543
],
[
543,
24,
1241
]
],
[
[
1123,
63,
1233
],
[
1233,
... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
... | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperam... |
DB00275 | DB00470 | 217 | 530 | [
"DDInter1330",
"DDInter601"
] | Olmesartan | Dronabinol | Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, w... | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Moderate | 1 | [
[
[
217,
24,
530
]
],
[
[
217,
24,
1614
],
[
1614,
40,
530
]
],
[
[
217,
21,
29226
],
[
29226,
60,
530
]
],
[
[
217,
24,
1376
],
[
1376,
... | [
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
... | Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone (Compound) resembles Dronabinol (Compound)
Olmesartan (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side Effect) is caused by Dronabinol (Compound)
Olmesartan may cause a moderate interaction that... |
DB01155 | DB06176 | 872 | 1,342 | [
"DDInter813",
"DDInter1616"
] | Gemifloxacin | Romidepsin | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
872,
24,
1342
]
],
[
[
872,
62,
112
],
[
112,
23,
1342
]
],
[
[
872,
40,
956
],
[
956,
24,
1342
]
],
[
[
872,
63,
485
],
[
485,
... | [
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Gemifloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin may cause a moderate interaction th... |
DB00500 | DB00687 | 24 | 870 | [
"DDInter1831",
"DDInter747"
] | Tolmetin | Fludrocortisone | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
24,
24,
870
]
],
[
[
24,
24,
1220
],
[
1220,
40,
870
]
],
[
[
24,
63,
251
],
[
251,
40,
870
]
],
[
[
24,
21,
28977
],
[
28977,
6... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Fludrocor... |
DB08881 | DB09068 | 868 | 1,427 | [
"DDInter1925",
"DDInter1948"
] | Vemurafenib | Vortioxetine | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Moderate | 1 | [
[
[
868,
24,
1427
]
],
[
[
868,
24,
1320
],
[
1320,
63,
1427
]
],
[
[
868,
64,
477
],
[
477,
24,
1427
]
],
[
[
868,
63,
1061
],
[
1061,
... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Vemurafenib may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may cause ... |
DB00619 | DB01181 | 1,419 | 1,532 | [
"DDInter909",
"DDInter906"
] | Imatinib | Ifosfamide | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1419,
24,
1532
]
],
[
[
1419,
5,
11555
],
[
11555,
44,
1532
]
],
[
[
1419,
6,
7524
],
[
7524,
45,
1532
]
],
[
[
1419,
21,
28956
],
[
2... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Imatinib",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) i... | Imatinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ifosfamide (Compound)
Imatinib (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Ifosfamide (Compound)
Imatinib (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Ifosf... |
DB01105 | DB04837 | 222 | 649 | [
"DDInter1665",
"DDInter407"
] | Sibutramine | Clofedanol | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
222,
24,
649
]
],
[
[
222,
63,
1376
],
[
1376,
24,
649
]
],
[
[
222,
64,
21
],
[
21,
24,
649
]
],
[
[
222,
64,
675
],
[
675,
40,... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Sibutramine may lead to a major life threatening interaction when taken with Amitriptyline and Amitri... |
DB00307 | DB00687 | 1,101 | 870 | [
"DDInter202",
"DDInter747"
] | Bexarotene | Fludrocortisone | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
1101,
24,
870
]
],
[
[
1101,
24,
1220
],
[
1220,
40,
870
]
],
[
[
1101,
25,
303
],
[
303,
40,
870
]
],
[
[
1101,
21,
28835
],
[
28835,... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Bexarotene may lead to a major life threatening interaction when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate (Compound) re... |
DB00889 | DB01242 | 1,133 | 1,237 | [
"DDInter840",
"DDInter410"
] | Granisetron | Clomipramine | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Major | 2 | [
[
[
1133,
25,
1237
]
],
[
[
1133,
64,
684
],
[
684,
1,
1237
]
],
[
[
1133,
63,
1630
],
[
1630,
1,
1237
]
],
[
[
1133,
24,
401
],
[
401,
... | [
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clomipramine"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
... | Granisetron may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Clomipramine (Compound)
G... |
DB06643 | DB12498 | 1,136 | 76 | [
"DDInter500",
"DDInter1238"
] | Denosumab | Mogamulizumab | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become canc... | Moderate | 1 | [
[
[
1136,
24,
76
]
],
[
[
1136,
63,
1531
],
[
1531,
24,
76
]
],
[
[
1136,
24,
384
],
[
384,
24,
76
]
],
[
[
1136,
24,
676
],
[
676,
... | [
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
... | Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Ide... |
DB09104 | DB11978 | 286 | 124 | [
"DDInter1118",
"DDInter822"
] | Magnesium hydroxide | Glasdegib | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
286,
24,
124
]
],
[
[
286,
63,
1079
],
[
1079,
24,
124
]
],
[
[
286,
24,
180
],
[
180,
63,
124
]
],
[
[
286,
62,
752
],
[
752,
2... | [
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin... | Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Olic... |
DB01072 | DB01190 | 915 | 568 | [
"DDInter129",
"DDInter398"
] | Atazanavir | Clindamycin | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bac... | Moderate | 1 | [
[
[
915,
24,
568
]
],
[
[
915,
6,
8374
],
[
8374,
45,
568
]
],
[
[
915,
21,
29278
],
[
29278,
60,
568
]
],
[
[
915,
24,
609
],
[
609,
... | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Atazanavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Atazanavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clindamycin (Compound)
Atazanavir (Compound) causes Inflammation (Side Effect) and Inflammation (Side Effect) is caused by Clindamycin (Compound)
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Clarithromy... |
DB00331 | DB00774 | 1,645 | 1,577 | [
"DDInter1164",
"DDInter889"
] | Metformin | Hydroflumethiazide | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Moderate | 1 | [
[
[
1645,
24,
1577
]
],
[
[
1645,
24,
359
],
[
359,
40,
1577
]
],
[
[
1645,
24,
504
],
[
504,
1,
1577
]
],
[
[
1645,
18,
6718
],
[
6718,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Hydroflumethiazide (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) ... |
DB00814 | DB01344 | 1,171 | 1,231 | [
"DDInter1143",
"DDInter1830"
] | Meloxicam | Tolevamer | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, H... | Major | 2 | [
[
[
1171,
25,
1231
]
],
[
[
1171,
24,
1486
],
[
1486,
24,
1231
]
],
[
[
1171,
63,
1573
],
[
1573,
24,
1231
]
],
[
[
1171,
24,
1019
],
[
10... | [
[
[
"Meloxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolevamer"
]
],
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methy... | Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Predniso... |
DB00531 | DB01124 | 450 | 1,411 | [
"DDInter456",
"DDInter1828"
] | Cyclophosphamide | Tolbutamide | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
450,
24,
1411
]
],
[
[
450,
24,
959
],
[
959,
40,
1411
]
],
[
[
450,
63,
245
],
[
245,
40,
1411
]
],
[
[
450,
6,
10215
],
[
10215,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
... | Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutami... |
DB06655 | DB09100 | 5 | 320 | [
"DDInter1077",
"DDInter1799"
] | Liraglutide | Thyroid, porcine | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyro... | Moderate | 1 | [
[
[
5,
24,
320
]
],
[
[
5,
63,
417
],
[
417,
23,
320
]
],
[
[
5,
63,
1144
],
[
1144,
24,
320
]
],
[
[
5,
24,
1296
],
[
1296,
63,
... | [
[
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
... | Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and... |
DB04908 | DB11730 | 1,671 | 351 | [
"DDInter741",
"DDInter1588"
] | Flibanserin | Ribociclib | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1671,
25,
351
]
],
[
[
1671,
63,
222
],
[
222,
23,
351
]
],
[
[
1671,
25,
283
],
[
283,
62,
351
]
],
[
[
1671,
64,
597
],
[
597,
... | [
[
[
"Flibanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Flibanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutra... | Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Flibanserin may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may caus... |
DB00333 | DB01128 | 576 | 918 | [
"DDInter1166",
"DDInter204"
] | Methadone | Bicalutamide | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Major | 2 | [
[
[
576,
25,
918
]
],
[
[
576,
25,
129
],
[
129,
40,
918
]
],
[
[
576,
6,
8374
],
[
8374,
45,
918
]
],
[
[
576,
21,
28642
],
[
28642,
... | [
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
]
],
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{... | Methadone may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Methadone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bicalutamide (Compound)
Methadone (Compound) causes Shock (Side Effect) and Shock (Side Effect) is ... |
DB08871 | DB09074 | 36 | 1,362 | [
"DDInter666",
"DDInter1327"
] | Eribulin | Olaparib | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
36,
24,
1362
]
],
[
[
36,
63,
896
],
[
896,
24,
1362
]
],
[
[
36,
64,
576
],
[
576,
24,
1362
]
],
[
[
36,
24,
1619
],
[
1619,
63... | [
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Et... | Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Eribulin may lead to a major life threatening interaction when taken with Methadone and Methadone may cause a moderate... |
DB01406 | DB06595 | 984 | 1,491 | [
"DDInter472",
"DDInter1214"
] | Danazol | Midostaurin | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
984,
24,
1491
]
],
[
[
984,
25,
1135
],
[
1135,
62,
1491
]
],
[
[
984,
24,
761
],
[
761,
24,
1491
]
],
[
[
984,
24,
1017
],
[
1017,
... | [
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Danazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Danazol may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moder... |
DB00836 | DB01035 | 543 | 1,401 | [
"DDInter1088",
"DDInter1524"
] | Loperamide | Procainamide | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | A derivative of procaine with less CNS action. | Moderate | 1 | [
[
[
543,
24,
1401
]
],
[
[
543,
6,
12523
],
[
12523,
45,
1401
]
],
[
[
543,
21,
28658
],
[
28658,
60,
1401
]
],
[
[
543,
24,
112
],
[
112,... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Loperamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)... | Loperamide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Procainamide (Compound)
Loperamide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Procainamide (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and... |
DB00312 | DB06697 | 1,023 | 436 | [
"DDInter1423",
"DDInter121"
] | Pentobarbital | Artemether | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</... | Moderate | 1 | [
[
[
1023,
24,
436
]
],
[
[
1023,
6,
8374
],
[
8374,
45,
436
]
],
[
[
1023,
24,
353
],
[
353,
24,
436
]
],
[
[
1023,
24,
214
],
[
214,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Artemether"
]
],
[
[
"Pentobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Pentobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Artemether (Compound)
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Artemether
Pentobar... |
DB00765 | DB01246 | 1,266 | 820 | [
"DDInter1205",
"DDInter45"
] | Metyrosine | Alimemazine | An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1266,
24,
820
]
],
[
[
1266,
24,
104
],
[
104,
40,
820
]
],
[
[
1266,
24,
401
],
[
401,
24,
820
]
],
[
[
1266,
24,
649
],
[
649,
... | [
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[... | Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction t... |
DB01259 | DB04953 | 392 | 495 | [
"DDInter1024",
"DDInter708"
] | Lapatinib | Ezogabine | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Moderate | 1 | [
[
[
392,
24,
495
]
],
[
[
392,
21,
28787
],
[
28787,
60,
495
]
],
[
[
392,
23,
1135
],
[
1135,
62,
495
]
],
[
[
392,
62,
112
],
[
112,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Lapatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is cause... | Lapatinib (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Ezogabine (Compound)
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ezogabine
Lapa... |
DB00024 | DB11827 | 818 | 433 | [
"DDInter1800",
"DDInter669"
] | Thyrotropin alfa | Ertugliflozin | Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cance... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
818,
24,
433
]
],
[
[
818,
24,
959
],
[
959,
24,
433
]
],
[
[
818,
24,
959
],
[
959,
62,
1103
],
[
1103,
23,
433
]
],
[
[
818,
2... | [
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
... | Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Glipizid... |
DB00938 | DB09045 | 455 | 52 | [
"DDInter1635",
"DDInter607"
] | Salmeterol | Dulaglutide | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
455,
24,
52
]
],
[
[
455,
24,
170
],
[
170,
23,
52
]
],
[
[
455,
24,
280
],
[
280,
24,
52
]
],
[
[
455,
25,
609
],
[
609,
24,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine and Me... |
DB01128 | DB09049 | 918 | 1,135 | [
"DDInter204",
"DDInter1261"
] | Bicalutamide | Naloxegol | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Minor | 0 | [
[
[
918,
23,
1135
]
],
[
[
918,
64,
33
],
[
33,
23,
1135
]
],
[
[
918,
24,
495
],
[
495,
23,
1135
]
],
[
[
918,
24,
971
],
[
971,
62... | [
[
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Bicalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodaron... | Bicalutamide may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine and Ezogabine may cause a... |
DB00445 | DB05812 | 322 | 1,374 | [
"DDInter655",
"DDInter8"
] | Epirubicin | Abiraterone | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
322,
24,
1374
]
],
[
[
322,
24,
1561
],
[
1561,
1,
1374
]
],
[
[
322,
5,
11562
],
[
11562,
44,
1374
]
],
[
[
322,
6,
10417
],
[
10417,... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
],
[... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Abiraterone (Compound)
Epirubicin (Compound) treats prostate cancer (Disease) and prostate cancer (Disease) is treated by Abiraterone (Compound)
Epirubicin (Compound) binds ABCC1... |
DB08815 | DB09564 | 154 | 1,296 | [
"DDInter1104",
"DDInter930"
] | Lurasidone | Insulin degludec | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
154,
24,
1296
]
],
[
[
154,
63,
274
],
[
274,
23,
1296
]
],
[
[
154,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
154,
24,
52
],
[
52,
... | [
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
],
... | Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide a... |
DB11248 | DB11921 | 1,193 | 1,019 | [
"DDInter1965",
"DDInter492"
] | Zinc gluconate | Deflazacort | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA. It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wit... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Minor | 0 | [
[
[
1193,
23,
1019
]
],
[
[
1193,
23,
270
],
[
270,
63,
1019
]
],
[
[
1193,
62,
629
],
[
629,
24,
1019
]
],
[
[
1193,
23,
1316
],
[
1316,
... | [
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Deflazacort"
]
],
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ocrelizumab"
],
... | Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Sirolimus and ... |
DB00388 | DB06701 | 1,636 | 1,177 | [
"DDInter1453",
"DDInter521"
] | Phenylephrine | Dexmethylphenidate | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Dexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD)[Label,A177181]. The d-isomer is thought to have greater effect with fewer s... | Moderate | 1 | [
[
[
1636,
24,
1177
]
],
[
[
1636,
24,
895
],
[
895,
1,
1177
]
],
[
[
1636,
24,
19
],
[
19,
40,
1177
]
],
[
[
1636,
21,
28703
],
[
28703,
... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexmethylphenidate"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylphenida... | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Methylphenidate and Methylphenidate (Compound) resembles Dexmethylphenidate (Compound)
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine (Compound) resemb... |
DB00137 | DB06755 | 518 | 1,355 | [
"DDInter1107",
"DDInter194"
] | Lutein | Beta carotene | Lutein is an xanthophyll and one of 600 known naturally occurring carotenoids. Lutein is synthesized only by plants and like other xanthophylls is found in high quantities in green leafy vegetables such as spinach, kale and yellow carrots. In green plants, xanthophylls act to modulate light energy and serve as non-phot... | Beta-carotene, with the molecular formula C40H56, belongs to the group of carotenoids consisting of isoprene units. The presence of long chains of conjugated double bonds donates beta-carotene with specific colors. It is the most abundant form of carotenoid and it is a precursor of the vitamin A. Beta-carotene is compo... | Minor | 0 | [
[
[
518,
23,
1355
]
]
] | [
[
[
"Lutein",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Beta carotene"
]
]
] | |
DB00279 | DB00624 | 1,152 | 1,561 | [
"DDInter1074",
"DDInter1775"
] | Liothyronine | Testosterone | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual charact... | Moderate | 1 | [
[
[
1152,
24,
1561
]
],
[
[
1152,
24,
155
],
[
155,
1,
1561
]
],
[
[
1152,
24,
1026
],
[
1026,
40,
1561
]
],
[
[
1152,
6,
1829
],
[
1829,
... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxymesterone"
... | Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Fluoxymesterone and Fluoxymesterone (Compound) resembles Testosterone (Compound)
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone and Oxandrolone (Compound) resembles Test... |
DB00852 | DB01105 | 1,445 | 222 | [
"DDInter1545",
"DDInter1665"
] | Pseudoephedrine | Sibutramine | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
1445,
24,
222
]
],
[
[
1445,
6,
6112
],
[
6112,
45,
222
]
],
[
[
1445,
21,
28698
],
[
28698,
60,
222
]
],
[
[
1445,
63,
847
],
[
847,
... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A4"
],
[
"SLC6A4",
"{u} (Gene) is bound by {v} (... | Pseudoephedrine (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Sibutramine (Compound)
Pseudoephedrine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Sibutramine (Compound)
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Atom... |
DB01320 | DB09045 | 651 | 52 | [
"DDInter783",
"DDInter607"
] | Fosphenytoin | Dulaglutide | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
651,
24,
52
]
],
[
[
651,
63,
170
],
[
170,
23,
52
]
],
[
[
651,
63,
609
],
[
609,
24,
52
]
],
[
[
651,
25,
1491
],
[
1491,
24,
... | [
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin a... |
DB04868 | DB11791 | 478 | 785 | [
"DDInter1293",
"DDInter287"
] | Nilotinib | Capmatinib | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
478,
24,
785
]
],
[
[
478,
63,
837
],
[
837,
23,
785
]
],
[
[
478,
24,
101
],
[
101,
23,
785
]
],
[
[
478,
23,
1135
],
[
1135,
2... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and D... |
DB00615 | DB00687 | 690 | 870 | [
"DDInter1589",
"DDInter747"
] | Rifabutin | Fludrocortisone | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
690,
24,
870
]
],
[
[
690,
24,
1220
],
[
1220,
40,
870
]
],
[
[
690,
63,
251
],
[
251,
40,
870
]
],
[
[
690,
21,
28751
],
[
28751,
... | [
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Fludroc... |
DB00595 | DB01390 | 1,545 | 1,117 | [
"DDInter1374",
"DDInter1683"
] | Oxytetracycline | Sodium bicarbonate | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Moderate | 1 | [
[
[
1545,
24,
1117
]
],
[
[
1545,
63,
663
],
[
663,
23,
1117
]
],
[
[
1545,
24,
954
],
[
954,
23,
1117
]
],
[
[
1545,
40,
1572
],
[
1572,
... | [
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrex... | Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Q... |
DB00004 | DB11943 | 669 | 255 | [
"DDInter499",
"DDInter495"
] | Denileukin diftitox | Delafloxacin | A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system. | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Minor | 0 | [
[
[
669,
23,
255
]
],
[
[
669,
23,
1176
],
[
1176,
23,
37
],
[
37,
23,
255
]
],
[
[
669,
23,
945
],
[
945,
62,
1686
],
[
1686,
23,
... | [
[
[
"Denileukin diftitox",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moxifloxaci... | Denileukin diftitox may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine and Lomustine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin... |
DB04861 | DB09156 | 1,592 | 777 | [
"DDInter1271",
"DDInter964"
] | Nebivolol | Iopromide | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Moderate | 1 | [
[
[
1592,
24,
777
]
],
[
[
1592,
24,
1013
],
[
1013,
63,
777
]
],
[
[
1592,
63,
1648
],
[
1648,
24,
777
]
],
[
[
1592,
24,
512
],
[
512,
... | [
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
]
],
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tyropanoic acid"
],
[
... | Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid and Tyropanoic acid may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin an... |
DB04908 | DB06605 | 1,671 | 1,409 | [
"DDInter741",
"DDInter108"
] | Flibanserin | Apixaban | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Moderate | 1 | [
[
[
1671,
24,
1409
]
],
[
[
1671,
25,
1593
],
[
1593,
63,
1409
]
],
[
[
1671,
63,
86
],
[
86,
24,
1409
]
],
[
[
1671,
24,
1374
],
[
1374,
... | [
[
[
"Flibanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Flibanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib... | Flibanserin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause ... |
DB01131 | DB08899 | 1,243 | 129 | [
"DDInter1531",
"DDInter649"
] | Proguanil | Enzalutamide | Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1243,
24,
129
]
],
[
[
1243,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1243,
21,
28809
],
[
28809,
60,
129
]
],
[
[
1243,
24,
286
],
[
286,
... | [
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Proguanil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Proguanil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Proguanil (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Enzalutamide (Compound)
Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxid... |
DB01035 | DB05294 | 1,401 | 1,069 | [
"DDInter1524",
"DDInter1917"
] | Procainamide | Vandetanib | A derivative of procaine with less CNS action. | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
1401,
25,
1069
]
],
[
[
1401,
21,
28921
],
[
28921,
60,
1069
]
],
[
[
1401,
63,
1194
],
[
1194,
23,
1069
]
],
[
[
1401,
62,
112
],
[
1... | [
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Procainamide",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (... | Procainamide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Vandetanib (Compound)
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Vande... |
DB00398 | DB14840 | 79 | 861 | [
"DDInter1702",
"DDInter1601"
] | Sorafenib | Ripretinib | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Moderate | 1 | [
[
[
79,
24,
861
]
],
[
[
79,
25,
351
],
[
351,
24,
861
]
],
[
[
79,
24,
214
],
[
214,
24,
861
]
],
[
[
79,
63,
1051
],
[
1051,
24,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",... | Sorafenib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may caus... |
DB00679 | DB09082 | 684 | 659 | [
"DDInter1796",
"DDInter1934"
] | Thioridazine | Vilanterol | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
684,
24,
659
]
],
[
[
684,
24,
870
],
[
870,
23,
659
]
],
[
[
684,
24,
1296
],
[
1296,
63,
659
]
],
[
[
684,
25,
927
],
[
927,
6... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],... | Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin d... |
DB00425 | DB06691 | 558 | 849 | [
"DDInter1970",
"DDInter1155"
] | Zolpidem | Mepyramine | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of s... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
558,
24,
849
]
],
[
[
558,
63,
1594
],
[
1594,
24,
849
]
],
[
[
558,
24,
272
],
[
272,
24,
849
]
],
[
[
558,
6,
12523
],
[
12523,
... | [
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlo... |
DB01215 | DB09054 | 1,418 | 384 | [
"DDInter677",
"DDInter905"
] | Estazolam | Idelalisib | A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1418,
24,
384
]
],
[
[
1418,
63,
222
],
[
222,
23,
384
]
],
[
[
1418,
40,
1565
],
[
1565,
24,
384
]
],
[
[
1418,
63,
723
],
[
723,
... | [
[
[
"Estazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Estazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Estazolam (Compound) resembles Clonazepam (Compound) and Clonazepam may cause a moderate interaction that could e... |
DB00398 | DB01118 | 79 | 33 | [
"DDInter1702",
"DDInter76"
] | Sorafenib | Amiodarone | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Major | 2 | [
[
[
79,
25,
33
]
],
[
[
79,
25,
540
],
[
540,
1,
33
]
],
[
[
79,
6,
7950
],
[
7950,
45,
33
]
],
[
[
79,
18,
9650
],
[
9650,
46,
... | [
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} (... | Sorafenib may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound)
Sorafenib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Amiodarone (Compound)
Sorafenib (Compound) downregulates HMGCS1 (Gene) and HMGCS1 (Gene) is upregulated... |
DB01175 | DB11113 | 318 | 657 | [
"DDInter672",
"DDInter307"
] | Escitalopram | Castor oil | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
318,
24,
657
]
],
[
[
318,
25,
927
],
[
927,
63,
657
]
],
[
[
318,
25,
1491
],
[
1491,
24,
657
]
],
[
[
318,
64,
1181
],
[
1181,
... | [
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encor... | Escitalopram may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Escitalopram may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moder... |
DB01156 | DB01618 | 593 | 776 | [
"DDInter252",
"DDInter1239"
] | Bupropion | Molindone | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to mo... | Major | 2 | [
[
[
593,
25,
776
]
],
[
[
593,
18,
6718
],
[
6718,
57,
776
]
],
[
[
593,
21,
28800
],
[
28800,
60,
776
]
],
[
[
593,
24,
1662
],
[
1662,
... | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Molindone"
]
],
[
[
"Bupropion",
"{u} (Compound) downregulates {v} (Gene)",
"USP22"
],
[
"USP22",
"{u} (Gene) is downregulated by {v} (Compound)",
... | Bupropion (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Molindone (Compound)
Bupropion (Compound) causes Dyskinesia (Side Effect) and Dyskinesia (Side Effect) is caused by Molindone (Compound)
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Picosulf... |
DB00108 | DB00773 | 1,066 | 896 | [
"DDInter1268",
"DDInter702"
] | Natalizumab | Etoposide | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Major | 2 | [
[
[
1066,
25,
896
]
],
[
[
1066,
25,
147
],
[
147,
23,
896
]
],
[
[
1066,
64,
58
],
[
58,
24,
896
]
],
[
[
1066,
25,
1362
],
[
1362,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etoposide"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u... | Natalizumab may lead to a major life threatening interaction when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Etoposide
Natalizumab may lead to a major life threatening interaction when taken with Alefacept and Alefacept may cause a moderate inter... |
DB01168 | DB01246 | 1,053 | 820 | [
"DDInter1526",
"DDInter45"
] | Procarbazine | Alimemazine | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1053,
24,
820
]
],
[
[
1053,
63,
104
],
[
104,
40,
820
]
],
[
[
1053,
64,
1335
],
[
1335,
24,
820
]
],
[
[
1053,
63,
401
],
[
401,
... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Procarbazine may lead to a major life threatening interaction when taken with Oxcarbazepine and Oxcarbazepine may cause a moderate interaction that could... |
DB00726 | DB11978 | 1,164 | 124 | [
"DDInter1876",
"DDInter822"
] | Trimipramine | Glasdegib | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1164,
24,
124
]
],
[
[
1164,
23,
112
],
[
112,
23,
124
]
],
[
[
1164,
63,
475
],
[
475,
24,
124
]
],
[
[
1164,
1,
9
],
[
9,
24,
... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Trimipramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Trimipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Mor... |
DB00959 | DB01122 | 1,486 | 158 | [
"DDInter1191",
"DDInter61"
] | Methylprednisolone | Ambenonium | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Ambenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis. | Moderate | 1 | [
[
[
1486,
24,
158
]
],
[
[
1486,
40,
870
],
[
870,
24,
158
]
],
[
[
1486,
25,
1011
],
[
1011,
63,
158
]
],
[
[
1486,
25,
770
],
[
770,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ambenonium"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
... | Methylprednisolone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ambenonium
Methylprednisolone may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction... |
DB00681 | DB00819 | 1,287 | 471 | [
"DDInter85",
"DDInter15"
] | Amphotericin B | Acetazolamide | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Moderate | 1 | [
[
[
1287,
24,
471
]
],
[
[
1287,
24,
997
],
[
997,
40,
471
]
],
[
[
1287,
21,
28929
],
[
28929,
60,
471
]
],
[
[
1287,
24,
891
],
[
891,
... | [
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
... | Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide and Methazolamide (Compound) resembles Acetazolamide (Compound)
Amphotericin B (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Acetazolamide (Compound)
Amphoter... |
DB01136 | DB09132 | 772 | 492 | [
"DDInter305",
"DDInter797"
] | Carvedilol | Gadoteric acid | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Gadoteric acid, commonly used in the salt form gadoterate meglumine, is a macrocyclic, ionic gadolinium-based contrast agent (GBCA). It is composed of the organic acid DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) used for its chelating properties, and gadolinium (Gd3+). Gadoterate meglumine has one o... | Moderate | 1 | [
[
[
772,
24,
492
]
],
[
[
772,
5,
11590
],
[
11590,
44,
1081
],
[
1081,
24,
492
]
],
[
[
772,
6,
5214
],
[
5214,
45,
1081
],
[
1081,
24,... | [
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadoteric acid"
]
],
[
[
"Carvedilol",
"{u} (Compound) treats {v} (Disease)",
"hypertension"
],
[
"hypertension",
"{u} (Disease) is tr... | Carvedilol (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Carvedilol (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is bound by Nicardipine (Compound... |
DB06616 | DB11978 | 594 | 124 | [
"DDInter224",
"DDInter822"
] | Bosutinib | Glasdegib | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
594,
24,
124
]
],
[
[
594,
62,
1247
],
[
1247,
23,
124
]
],
[
[
594,
24,
327
],
[
327,
24,
124
]
],
[
[
594,
63,
1079
],
[
1079,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Bosutinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Bosutinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir and A... |
DB00333 | DB00771 | 576 | 262 | [
"DDInter1166",
"DDInter397"
] | Methadone | Clidinium | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Moderate | 1 | [
[
[
576,
35,
262
]
],
[
[
576,
35,
1511
],
[
1511,
63,
262
]
],
[
[
576,
1,
1688
],
[
1688,
1,
262
]
],
[
[
576,
1,
704
],
[
704,
63... | [
[
[
"Methadone",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
],
[
[
"Methadone",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction th... | Methadone (Compound) resembles Clidinium (Compound) and
Methadone (Compound) resembles Mepenzolate (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Clidiniu... |
DB00938 | DB06694 | 455 | 31 | [
"DDInter1635",
"DDInter1952"
] | Salmeterol | Xylometazoline (nasal) | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Xylometazoline is an alkylbenzene. | Moderate | 1 | [
[
[
455,
24,
31
]
],
[
[
455,
18,
2976
],
[
2976,
57,
31
]
],
[
[
455,
63,
87
],
[
87,
24,
31
]
],
[
[
455,
24,
144
],
[
144,
63,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Xylometazoline"
]
],
[
[
"Salmeterol",
"{u} (Compound) downregulates {v} (Gene)",
"STUB1"
],
[
"STUB1",
"{u} (Gene) is downregulated b... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Salmeterol (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Xylometazoline (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine a... |
DB01174 | DB11834 | 697 | 1,303 | [
"DDInter1442",
"DDInter849"
] | Phenobarbital | Guselkumab | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Moderate | 1 | [
[
[
697,
24,
1303
]
],
[
[
697,
25,
792
],
[
792,
24,
1303
]
],
[
[
697,
63,
58
],
[
58,
24,
1303
]
],
[
[
697,
62,
608
],
[
608,
24... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
"Riv... | Phenobarbital may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may ... |
DB00242 | DB00900 | 1,064 | 45 | [
"DDInter392",
"DDInter544"
] | Cladribine | Didanosine | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Moderate | 1 | [
[
[
1064,
24,
45
]
],
[
[
1064,
40,
1524
],
[
1524,
1,
45
]
],
[
[
1064,
6,
4071
],
[
4071,
45,
45
]
],
[
[
1064,
7,
4456
],
[
4456,
... | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Didanosine"
]
],
[
[
"Cladribine",
"{u} (Compound) resembles {v} (Compound)",
"Entecavir"
],
[
"Entecavir",
"{u} (Compound) resembles ... | Cladribine (Compound) resembles Entecavir (Compound) and Entecavir (Compound) resembles Didanosine (Compound)
Cladribine (Compound) binds PNP (Gene) and PNP (Gene) is bound by Didanosine (Compound)
Cladribine (Compound) upregulates NOTCH1 (Gene) and NOTCH1 (Gene) is upregulated by Didanosine (Compound)
Cladribine (Comp... |
DB06414 | DB11703 | 655 | 405 | [
"DDInter703",
"DDInter9"
] | Etravirine | Acalabrutinib | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
655,
24,
405
]
],
[
[
655,
63,
1051
],
[
1051,
24,
405
]
],
[
[
655,
62,
1101
],
[
1101,
24,
405
]
],
[
[
655,
24,
1446
],
[
1446,
... | [
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
]... | Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Etravirine may cause a minor interaction that can limit clinical effects when taken with Bexaro... |
DB00604 | DB11986 | 1,425 | 484 | [
"DDInter385",
"DDInter648"
] | Cisapride | Entrectinib | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
1425,
25,
484
]
],
[
[
1425,
23,
1247
],
[
1247,
23,
484
]
],
[
[
1425,
25,
1539
],
[
1539,
24,
484
]
],
[
[
1425,
64,
322
],
[
322,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Cisapride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfame... | Cisapride may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Cisapride may lead to a major life threatening interaction when taken with Ofloxacin and Ofloxacin may c... |
DB00607 | DB00618 | 1,249 | 1,572 | [
"DDInter1256",
"DDInter498"
] | Nafcillin | Demeclocycline | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be u... | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Moderate | 1 | [
[
[
1249,
24,
1572
]
],
[
[
1249,
24,
1620
],
[
1620,
1,
1572
]
],
[
[
1249,
63,
964
],
[
964,
1,
1572
]
],
[
[
1249,
24,
1669
],
[
1669,
... | [
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
]
],
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
],
... | Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline (Compound) resembles Demeclocycline (Compound)
Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline (Compound) resembles Demeclocycline... |
DB01082 | DB01400 | 1,448 | 1,372 | [
"DDInter1713",
"DDInter1279"
] | Streptomycin | Neostigmine | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. | Moderate | 1 | [
[
[
1448,
24,
1372
]
],
[
[
1448,
63,
751
],
[
751,
40,
1372
]
],
[
[
1448,
21,
28787
],
[
28787,
60,
1372
]
],
[
[
1448,
24,
1662
],
[
16... | [
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyridostigmine"
],... | Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Pyridostigmine and Pyridostigmine (Compound) resembles Neostigmine (Compound)
Streptomycin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Neostigmine (Compound)
Streptomycin may cause a mod... |
DB00285 | DB00434 | 1,100 | 13 | [
"DDInter1927",
"DDInter459"
] | Venlafaxine | Cyproheptadine | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Moderate | 1 | [
[
[
1100,
24,
13
]
],
[
[
1100,
24,
1219
],
[
1219,
63,
13
]
],
[
[
1100,
6,
7390
],
[
7390,
45,
13
]
],
[
[
1100,
21,
29455
],
[
29455,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
],
... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Venlafaxine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Cyproheptadine (Compound)
Venlafaxin... |
DB01229 | DB13179 | 973 | 68 | [
"DDInter1378",
"DDInter1882"
] | Paclitaxel (protein-bound) | Troleandomycin | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | A macrolide antibiotic that is similar to erythromycin. | Moderate | 1 | [
[
[
973,
24,
68
]
],
[
[
973,
63,
1101
],
[
1101,
23,
68
]
],
[
[
973,
24,
1374
],
[
1374,
23,
68
]
],
[
[
973,
24,
309
],
[
309,
24... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Pacl... |
DB00370 | DB00857 | 1,251 | 1,387 | [
"DDInter1230",
"DDInter1768"
] | Mirtazapine | Terbinafine | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Moderate | 1 | [
[
[
1251,
24,
1387
]
],
[
[
1251,
6,
8374
],
[
8374,
45,
1387
]
],
[
[
1251,
6,
3576
],
[
3576,
46,
1387
]
],
[
[
1251,
21,
29047
],
[
290... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terbinafine"
]
],
[
[
"Mirtazapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Mirtazapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Terbinafine (Compound)
Mirtazapine (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is upregulated by Terbinafine (Compound)
Mirtazapine (Compound) causes Hepatic function abnormal (Side Effect) and Hepatic function abnormal (Side Effect) is caused ... |
DB01044 | DB01101 | 246 | 60 | [
"DDInter809",
"DDInter285"
] | Gatifloxacin | Capecitabine | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Minor | 0 | [
[
[
246,
23,
60
]
],
[
[
246,
21,
28688
],
[
28688,
60,
60
]
],
[
[
246,
1,
872
],
[
872,
62,
60
]
],
[
[
246,
40,
1176
],
[
1176,
2... | [
[
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Epistaxis"
],
[
"Epistaxis",
"{u} (Side Effect) is ... | Gatifloxacin (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Capecitabine (Compound)
Gatifloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Gatifloxacin (Compound) resembles ... |
DB00690 | DB01041 | 1,216 | 770 | [
"DDInter762",
"DDInter1789"
] | Flurazepam | Thalidomide | A benzodiazepine derivative used mainly as a hypnotic. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1216,
24,
770
]
],
[
[
1216,
6,
6365
],
[
6365,
45,
770
]
],
[
[
1216,
21,
28789
],
[
28789,
60,
770
]
],
[
[
1216,
24,
609
],
[
609,
... | [
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Flurazepam",
"{u} (Compound) binds {v} (Gene)",
"CYP2E1"
],
[
"CYP2E1",
"{u} (Gene) is bound by {v} (Compound)"... | Flurazepam (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Thalidomide (Compound)
Flurazepam (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Thalidomide (Compound)
Flurazepam may cause a moderate interaction that could exacerbate diseases when take... |
DB00582 | DB01246 | 1,622 | 820 | [
"DDInter1946",
"DDInter45"
] | Voriconazole | Alimemazine | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1622,
24,
820
]
],
[
[
1622,
24,
401
],
[
401,
24,
820
]
],
[
[
1622,
6,
8374
],
[
8374,
45,
820
]
],
[
[
1622,
21,
28662
],
[
28662,
... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Voriconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alimemazine (Compound)
Voricona... |
DB00682 | DB15066 | 126 | 445 | [
"DDInter1951",
"DDInter821"
] | Warfarin | Givosiran | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a... | Moderate | 1 | [
[
[
126,
24,
445
]
],
[
[
126,
24,
1039
],
[
1039,
24,
445
]
],
[
[
126,
63,
883
],
[
883,
24,
445
]
],
[
[
126,
23,
712
],
[
712,
2... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Ge... |
DB00307 | DB06603 | 1,101 | 39 | [
"DDInter202",
"DDInter1387"
] | Bexarotene | Panobinostat | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
1101,
24,
39
]
],
[
[
1101,
24,
479
],
[
479,
23,
39
]
],
[
[
1101,
63,
912
],
[
912,
24,
39
]
],
[
[
1101,
24,
221
],
[
221,
63... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and ... |
DB11827 | DB14509 | 433 | 1,399 | [
"DDInter669",
"DDInter1081"
] | Ertugliflozin | Lithium carbonate | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
433,
24,
1399
]
],
[
[
433,
63,
874
],
[
874,
23,
1399
]
],
[
[
433,
63,
820
],
[
820,
24,
1399
]
],
[
[
433,
24,
1476
],
[
1476,
... | [
[
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
... | Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Alimemaz... |
DB06700 | DB06704 | 643 | 247 | [
"DDInter511",
"DDInter951"
] | Desvenlafaxine | Iobenguane (I-123) | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Moderate | 1 | [
[
[
643,
37,
247
]
],
[
[
643,
6,
7390
],
[
7390,
45,
247
]
],
[
[
643,
21,
28787
],
[
28787,
60,
247
]
],
[
[
643,
63,
820
],
[
820,
... | [
[
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Desvenlafaxine",
"{u} (Compound) binds {v} (Gene)",
... | Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Desvenlafaxine may lead to a major life threatening interaction when taken with Iobenguane
Desvenlafaxine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound)
Desvenlafaxine (Compo... |
DB01319 | DB09030 | 34 | 840 | [
"DDInter777",
"DDInter1945"
] | Fosamprenavir | Vorapaxar | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Major | 2 | [
[
[
34,
25,
840
]
],
[
[
34,
24,
1017
],
[
1017,
63,
840
]
],
[
[
34,
24,
578
],
[
578,
24,
840
]
],
[
[
34,
25,
159
],
[
159,
63,
... | [
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorla... | Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and T... |
DB00619 | DB01222 | 1,419 | 617 | [
"DDInter909",
"DDInter246"
] | Imatinib | Budesonide | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
1419,
24,
617
]
],
[
[
1419,
63,
251
],
[
251,
1,
617
]
],
[
[
1419,
24,
175
],
[
175,
1,
617
]
],
[
[
1419,
6,
8374
],
[
8374,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Budesonide (Co... |
DB00872 | DB09330 | 1,080 | 985 | [
"DDInter438",
"DDInter1352"
] | Conivaptan | Osimertinib | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
1080,
25,
985
]
],
[
[
1080,
63,
168
],
[
168,
23,
985
]
],
[
[
1080,
64,
608
],
[
608,
23,
985
]
],
[
[
1080,
25,
1478
],
[
1478,
... | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomi... | Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Conivaptan may lead to a major life threatening interaction when taken with Lidocaine and Lidocaine may cause a m... |
DB11943 | DB12267 | 255 | 1,476 | [
"DDInter495",
"DDInter233"
] | Delafloxacin | Brigatinib | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
255,
24,
1476
]
],
[
[
255,
64,
176
],
[
176,
24,
1476
]
],
[
[
255,
63,
123
],
[
123,
24,
1476
]
],
[
[
255,
24,
1385
],
[
1385,
... | [
[
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Delafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Insulin glargine"
],
[
"... | Delafloxacin may lead to a major life threatening interaction when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenat... |
DB00673 | DB15328 | 723 | 829 | [
"DDInter112",
"DDInter1896"
] | Aprepitant | Ubrogepant | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Moderate | 1 | [
[
[
723,
24,
829
]
],
[
[
723,
25,
1476
],
[
1476,
24,
829
]
],
[
[
723,
24,
1468
],
[
1468,
24,
829
]
],
[
[
723,
63,
883
],
[
883,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib... | Aprepitant may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a ... |
DB01045 | DB08881 | 463 | 868 | [
"DDInter1590",
"DDInter1925"
] | Rifampicin | Vemurafenib | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
463,
25,
868
]
],
[
[
463,
6,
8374
],
[
8374,
45,
868
]
],
[
[
463,
18,
6665
],
[
6665,
57,
868
]
],
[
[
463,
62,
608
],
[
608,
... | [
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Rifampicin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemura... | Rifampicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Rifampicin (Compound) downregulates TIMP1 (Gene) and TIMP1 (Gene) is downregulated by Vemurafenib (Compound)
Rifampicin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may... |
DB00023 | DB00569 | 305 | 553 | [
"DDInter127",
"DDInter775"
] | Asparaginase Escherichia coli | Fondaparinux | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Moderate | 1 | [
[
[
305,
24,
553
]
],
[
[
305,
24,
1416
],
[
1416,
24,
553
]
],
[
[
305,
24,
901
],
[
901,
63,
553
]
],
[
[
305,
24,
477
],
[
477,
6... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fondaparinux"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with ... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib and Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Fondaparinux
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases... |
DB08907 | DB09129 | 1,344 | 625 | [
"DDInter280",
"DDInter373"
] | Canagliflozin | Chromic chloride | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN). | Moderate | 1 | [
[
[
1344,
24,
625
]
],
[
[
1344,
40,
549
],
[
549,
24,
625
]
],
[
[
1344,
63,
473
],
[
473,
24,
625
]
],
[
[
1344,
24,
1296
],
[
1296,
... | [
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromic chloride"
]
],
[
[
"Canagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} m... | Canagliflozin (Compound) resembles Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Chromic chloride
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate in... |
DB00741 | DB01254 | 167 | 1,213 | [
"DDInter885",
"DDInter484"
] | Hydrocortisone | Dasatinib | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
167,
24,
1213
]
],
[
[
167,
6,
17404
],
[
17404,
45,
1213
]
],
[
[
167,
7,
3361
],
[
3361,
46,
1213
]
],
[
[
167,
18,
2023
],
[
2023,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compou... | Hydrocortisone (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Dasatinib (Compound)
Hydrocortisone (Compound) upregulates NFIL3 (Gene) and NFIL3 (Gene) is upregulated by Dasatinib (Compound)
Hydrocortisone (Compound) downregulates RAP1GAP (Gene) and RAP1GAP (Gene) is upregulated by Dasatinib (Compound)
Hydro... |
DB00818 | DB06603 | 898 | 39 | [
"DDInter1538",
"DDInter1387"
] | Propofol | Panobinostat | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
898,
24,
39
]
],
[
[
898,
23,
112
],
[
112,
23,
39
]
],
[
[
898,
24,
455
],
[
455,
24,
39
]
],
[
[
898,
24,
1040
],
[
1040,
63,
... | [
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Propofol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Propofol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmet... |
DB01246 | DB11901 | 820 | 913 | [
"DDInter45",
"DDInter107"
] | Alimemazine | Apalutamide | A phenothiazine derivative that is used as an antipruritic. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
820,
24,
913
]
],
[
[
820,
63,
312
],
[
312,
23,
913
]
],
[
[
820,
62,
112
],
[
112,
23,
913
]
],
[
[
820,
63,
1322
],
[
1322,
2... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eplerenone"
],
[... | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Eplerenone and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Alimemazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metr... |
DB00307 | DB15328 | 1,101 | 829 | [
"DDInter202",
"DDInter1896"
] | Bexarotene | Ubrogepant | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Moderate | 1 | [
[
[
1101,
24,
829
]
],
[
[
1101,
25,
1476
],
[
1476,
24,
829
]
],
[
[
1101,
24,
578
],
[
578,
24,
829
]
],
[
[
1101,
23,
86
],
[
86,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib... | Bexarotene may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause ... |
DB00877 | DB10583 | 629 | 949 | [
"DDInter1678",
"DDInter415"
] | Sirolimus | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Moderate | 1 | [
[
[
629,
24,
949
]
],
[
[
629,
64,
589
],
[
589,
24,
949
]
],
[
[
629,
24,
250
],
[
250,
24,
949
]
],
[
[
629,
25,
1377
],
[
1377,
2... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Sirolimus may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Sirolimus may cause a moderate interaction that could exacerbate diseases when t... |
DB00802 | DB06282 | 1,322 | 516 | [
"DDInter43",
"DDInter1053"
] | Alfentanil | Levocetirizine | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
1322,
24,
516
]
],
[
[
1322,
63,
701
],
[
701,
24,
516
]
],
[
[
1322,
40,
1454
],
[
1454,
24,
516
]
],
[
[
1322,
24,
407
],
[
407,
... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
... | Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Alfentanil (Compound) resembles Sufentanil (Compound) and Sufentanil may cause a moderate interaction that c... |
DB00471 | DB09280 | 201 | 1,604 | [
"DDInter1242",
"DDInter1101"
] | Montelukast | Lumacaftor | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montel... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
201,
24,
1604
]
],
[
[
201,
24,
522
],
[
522,
24,
1604
]
],
[
[
201,
63,
254
],
[
254,
24,
1604
]
],
[
[
201,
24,
1033
],
[
1033,
... | [
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
],
[... | Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Ni... |
DB01400 | DB08865 | 1,372 | 1,593 | [
"DDInter1279",
"DDInter448"
] | Neostigmine | Crizotinib | A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
1372,
24,
1593
]
],
[
[
1372,
6,
4973
],
[
4973,
45,
1593
]
],
[
[
1372,
18,
3684
],
[
3684,
57,
1593
]
],
[
[
1372,
21,
28792
],
[
28... | [
[
[
"Neostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Neostigmine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Neostigmine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Crizotinib (Compound)
Neostigmine (Compound) downregulates PGAM1 (Gene) and PGAM1 (Gene) is downregulated by Crizotinib (Compound)
Neostigmine (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is c... |
DB11581 | DB11730 | 1,456 | 351 | [
"DDInter1926",
"DDInter1588"
] | Venetoclax | Ribociclib | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lym... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1456,
25,
351
]
],
[
[
1456,
64,
271
],
[
271,
23,
351
]
],
[
[
1456,
24,
466
],
[
466,
62,
351
]
],
[
[
1456,
25,
283
],
[
283,
... | [
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} m... | Venetoclax may lead to a major life threatening interaction when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may caus... |
DB06650 | DB15091 | 1,500 | 676 | [
"DDInter1324",
"DDInter1901"
] | Ofatumumab | Upadacitinib | Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
1500,
25,
676
]
],
[
[
1500,
24,
1430
],
[
1430,
24,
676
]
],
[
[
1500,
63,
248
],
[
248,
24,
676
]
],
[
[
1500,
63,
1184
],
[
1184,
... | [
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipule... | Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir ... |
DB01320 | DB11834 | 651 | 1,303 | [
"DDInter783",
"DDInter849"
] | Fosphenytoin | Guselkumab | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Moderate | 1 | [
[
[
651,
24,
1303
]
],
[
[
651,
25,
792
],
[
792,
24,
1303
]
],
[
[
651,
63,
58
],
[
58,
24,
1303
]
],
[
[
651,
62,
608
],
[
608,
24... | [
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
"Rivar... | Fosphenytoin may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may ca... |
DB08908 | DB09570 | 713 | 1,480 | [
"DDInter564",
"DDInter1002"
] | Dimethyl fumarate | Ixazomib | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
713,
24,
1480
]
],
[
[
713,
24,
987
],
[
987,
63,
1480
]
],
[
[
713,
63,
268
],
[
268,
24,
1480
]
],
[
[
713,
24,
1613
],
[
1613,
... | [
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae... | Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Dimethyl fumarate may cause a mod... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.